References
Institute for Clinical and Economic Review. Modulator treatments for cystic fibrosis: effectiveness and value. 2020. https://icer.org/wp-content/uploads/2020/08/ICER_CF_Final_Report_092320.pdf. Accessed 7 Jan 2023.
Office of Representative Katie Porter. Skyrocketing: how big pharma exploits launch pricest to cash in on cancer. 2020. https://porter.house.gov/uploadedfiles/skyrocketing_-_how_big_pharma_exploits_launch_prices_to_cash_in_on_cancer.pdf. Accessed 7 Jan 2023.
Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14:381–90.
Dusetzina SB, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, et al. Many Medicare beneficiaries do not fill high-price specialty drug prescriptions. Health Aff. 2022;41:487–96.
Yabroff KR, Dowling EC, Guy GP Jr., Banegas MP, Davidoff A, Han X, et al. Financial hardship associated with cancer in the united states: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34:259–67.
Nayak RK, Lee CC, Avorn J, Kesselheim AS. Public-sector contributions to novel biologic drugs. JAMA Intern Med. 2021;181:1522–5.
Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. PNAS. 2018;115:2329–34.
Edwards M, Murray F, Yu R. Gold in the ivory tower: equity rewards of outlicensing. Nat Biotechnol. 2006;24:509–15.
AUTM. AUTM 2020 Licensing Activity Survey. 2021. https://register.autm.net/detail.aspx?id=2020_APPENDIX. Accessed 7 Jan 2023.
Mission Statement of the Perelman School of Medicine. https://www.med.upenn.edu/psom/overview.html. Accessed 7 Jan 2023.
Chokshi DA. Improving access to medicines in poor countries: the role of universities. PLoS Med. 2006;3:e136.
Nguyen T-Y, Veras J, Shahzad MA. Recent experiences in policy implementation of socially responsible licensing in select universities across Europe and North America: identifying key provisions to promote global access to health technologies. Les Nouvelles. 2018;53. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3218516. Accessed 7 Jan 2023.
AUTM. Nine Points to Consider in Licensing University Technology. 2007. https://autm.net/about-tech-transfer/principles-and-guidelines/nine-points-to-consider-when-licensing-university. Accessed 7 Jan 2023.
Contreras JL “In the public interest” – University technology transfer and the Nine Points Document – an empirical assessment. U.C. Irvine L Rev. 2022;12: forthcoming. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3990450. Accessed 7 Jan 2023.
National Research Council. Managing university intellectual property in the public interest. Washington, DC: The National Academies Press: 2011. https://nap.nationalacademies.org/catalog/13001/managing-university-intellectual-property-in-the-public-interest. Accessed 7 Jan 2023.
Fernandez Lynch H, Bateman-House A, Rivera SM. Academic advocacy: opportunities to influence health and science policy under U.S. lobbying law. Acad Med. 2020;95:44–51.
Gagnon D, Ming E. Higher education is investing in ESG. https://info.kpmg.us/news-perspectives/advancing-the-profession/higher-ed-investing-in-esg.html. Accessed 7 Jan 2023.
Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the united states: origins and prospects for reform. JAMA. 2016;316:858–71.
Patent and Trademark Law Amendments Act of 1980, Pub. L. 96-517, 94 Stat. 3015 (December 12, 1980), codified at 35 U.S.C. §§ 200–212.
Acknowledgements
The authors thank Katharine Gleason, MPH and Mariah Johnson, MPH for research assistance and administrative support. The authors also thank Merith Basey, MSc, Rebecca Eisenberg, JD, Sarah Emond, MPP, Heather Pierce, JD, MPH, Reshma Ramachandran, MD, MPP, MHS, and Jon Soderstrom, PhD for helpful discussions that informed the arguments presented herein (acknowledgment does not necessarily imply agreement).
Funding
The research presented here was funded by a grant to the University of Pennsylvania from the National Center for Advancing Translational Research (NCATS) of the National Institutes of Health (5UL1TR001878). The sponsor had no input into this research or publication.
Author information
Authors and Affiliations
Contributions
All authors contributed to the research and arguments presented in this article. SJ wrote the first draft of the manuscript; all authors revised it critically for important intellectual content. All authors approved the final draft of the manuscript.
Corresponding author
Ethics declarations
Competing interests
SJ reports receiving research funding from Pfizer through the University of Pennsylvania until May 2020 and is a member of a Data and Safety Monitoring Board for CSL Behring. DM is a patient with incurable blood cancer. He is Founder of Patients for Affordable Drugs (P4AD), a not-for-profit organization, for which he serves as an unpaid volunteer. P4AD does not accept funding from any organizations that profit from development or distribution of prescription drugs. RES reports receiving grant funding and personal fees from the Institute for Clinical and Economic Review, the National Academy for State Health Policy, and West Health. HFL reports research funding from Arnold Ventures and consulting with the Robert Wood Johnson Foundation outside the present work. RMC, JLC, EAL, MSM, and AMW have no financial relationships to report.
Ethical approval
No ethical approval was required as this research did not involve human or animal subjects.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Joffe, S., Conti, R.M., Contreras, J.L. et al. Access to affordable medicines: obligations of universities and academic medical centers. Gene Ther 30, 753–755 (2023). https://doi.org/10.1038/s41434-023-00393-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41434-023-00393-2
- Springer Nature Limited
This article is cited by
-
Correction: Cost of gene therapy
Gene Therapy (2024)
-
Cost of gene therapy
Gene Therapy (2023)